This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mushtaq, S.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mushtaq, S.
Right arrow Articles by Livermore, D. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2004, p. 1313-1319, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1313-1319.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized ß-Lactamases

Shazad Mushtaq,1 Yigong Ge,2 and David M. Livermore1*

Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency Colindale, London, NW9 5HT, United Kingdom,1 Peninsula Pharmaceuticals, Inc., Alameda, California 945022

Received 19 August 2003/ Returned for modification 4 November 2003/ Accepted 9 December 2003

Doripenem (S-4661), a new parenteral carbapenem, was tested against over 250 clinical isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp., selected or derived for their ß-lactamase expression characteristics. Imipenem, meropenem, and ertapenem were tested as comparators, along with cephalosporins and piperacillin-tazobactam, by using National Committee for Clinical Laboratory Standards agar dilution methodology. Doripenem MICs were from 0.03 to 0.25 µg/ml for Klebsiella isolates, irrespective of the presence of extended-spectrum ß-lactamases (ESBLs) or plasmid-mediated AmpC or hyperproduced K1 ß-lactamase. Similarly, MICs of doripenem for both AmpC-inducible and -derepressed Enterobacter isolates were 0.06 to 0.5 µg/ml. ESBL production did not raise the MICs of doripenem for Escherichia coli transconjugants, and studies with known expression mutants confirmed that neither inducible nor depressed AmpC ß-lactamase expression was protective in Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, or Morganella morganii. In all of these respects, doripenem resembled meropenem and imipenem, whereas the MICs of ertapenem were raised (but still <=1 µg/ml) for many ESBL-producing klebsiellas and AmpC-derepressed E. cloacae and C. freundii strains. Resistance to all carbapenems, including doripenem (MICs of mostly 16 to 64 µg/ml, compared with 0.25 to 1 µg/ml for typical strains), was seen in Acinetobacter isolates with metallo-ß-lactamases or OXA-carbapenemases. Isolates of Klebsiella and Serratia spp. with IMP, KPC, and SME ß-lactamases also were resistant to doripenem (MICs, 8 to >64 µg/ml) and to other carbapenems, although the continued apparent susceptibility (MICs, <=0.5 µg/ml) of E. coli derivatives with cloned IMP-1 and NMC-A ß-lactamases suggested that carbapenem resistance might require other factors besides the enzymes.

* Corresponding author. Mailing address: Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Colindale, 61 Colindale Ave., London NW9 5HT, United Kingdom. Phone: 44 20-8200-4400. Fax: 44 20-8358-3292. E-mail: david.livermore{at}hpa.org.uk.

Antimicrobial Agents and Chemotherapy, April 2004, p. 1313-1319, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1313-1319.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Livermore, D. M., Mushtaq, S., Warner, M. (2009). Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 64: 330-335 [Abstract] [Full Text]  
  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Cirillo, I., Vaccaro, N., Turner, K., Solanki, B., Natarajan, J., Redman, R. (2009). Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers. J Clin Pharmacol 49: 798-806 [Abstract] [Full Text]  
  • Pillar, C. M., Torres, M. K., Brown, N. P., Shah, D., Sahm, D. F. (2008). In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States. Antimicrob. Agents Chemother. 52: 4388-4399 [Abstract] [Full Text]  
  • Snydman, D. R., Jacobus, N. V., McDermott, L. A. (2008). In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 52: 4492-4496 [Abstract] [Full Text]  
  • Cirillo, I., Mannens, G., Janssen, C., Vermeir, M., Cuyckens, F., Desai-Krieger, D., Vaccaro, N., Kao, L. M., Devineni, D., Redman, R., Turner, K. (2008). Disposition, Metabolism, and Excretion of [14C]Doripenem after a Single 500-Milligram Intravenous Infusion in Healthy Men. Antimicrob. Agents Chemother. 52: 3478-3483 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  
  • Mushtaq, S., Warner, M., Ge, Y., Kaniga, K., Livermore, D. M. (2007). In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 60: 300-311 [Abstract] [Full Text]  
  • Mushtaq, S., Hope, R., Warner, M., Livermore, D. M. (2007). Activity of faropenem against cephalosporin-resistant Enterobacteriaceae. J Antimicrob Chemother 59: 1025-1030 [Abstract] [Full Text]  
  • Alba, J., Ishii, Y., Thomson, K., Moland, E. S., Yamaguchi, K. (2005). Kinetics Study of KPC-3, a Plasmid-Encoded Class A Carbapenem-Hydrolyzing {beta}-Lactamase. Antimicrob. Agents Chemother. 49: 4760-4762 [Abstract] [Full Text]  
  • Chen, Y., Garber, E., Zhao, Q., Ge, Y., Wikler, M. A., Kaniga, K., Saiman, L. (2005). In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 49: 2510-2511 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2005). Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 55: 944-949 [Abstract] [Full Text]  
  • Jones, R. N., Huynh, H. K., Biedenbach, D. J. (2004). Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens. Antimicrob. Agents Chemother. 48: 3136-3140 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»